The paused liver transplant trial provided crucial learnings that informed Quell's pivot to autoimmune diseases. They discovered that high baseline inflammation improves cell engraftment and that durable targets lead to long-term cell activity. These insights gave them confidence to pursue autoimmune indications where these conditions are prevalent.

The success of early CAR-T cell therapies was partly luck. Future therapies face a high bar, as an ideal target must meet three criteria: 1) be abundant on cancer cells, 2) be indispensable for the cancer's survival, and 3) be dispensable for the patient's healthy tissues to avoid lethal toxicity.

CELMoDs are being actively trialed as a maintenance therapy after CAR T-cell treatment. The strategy is to leverage the CELMoDs' ability to enhance T-cell function and upregulate effector T-cells to boost the activity and persistence of the CAR-T product, potentially leading to more durable responses and preventing relapse.

Unlike some targeted therapies that lead to antigen loss, treatment with the CD19-directed antibody tafasitamab does not appear to eliminate CD19 expression on lymphoma cells. This is a critical finding, as it preserves the target for subsequent potent therapies like CD19-directed CAR T-cells.

Despite excitement for in-vivo CAR-Ts, the high response rates and multi-year survival of current autologous therapies create a significant competitive moat. New modalities must not only match this efficacy but also prove long-term durability, a high bar that insulates incumbents in indications like multiple myeloma for the foreseeable future.

Despite exciting early efficacy data for in vivo CAR-T therapies, the modality's future hinges on the critical unanswered question of durability. How long the therapeutic effects last, for which there is little data, will ultimately determine its clinical viability and applications in cancer versus autoimmune diseases.

The efficacy of Siltacel stems from a powerful initial expansion that eliminates cancer upfront. The CAR-T cells are often undetectable beyond six months, indicating their curative potential comes from an overwhelming initial response rather than persistent, long-term immune policing of the disease.

A core safety feature of Quell's platform is inserting an extra copy of the FOXP3 gene into its Treg cells. This 'phenotype locks' the cells, anchoring them in a suppressive state. This prevents them from flipping into pro-inflammatory 'attacking' cells, which is critical when they are engineered with a CAR to target specific tissues.

Create Medicines chose LNP-delivered RNA for its in vivo platform to give physicians control. Unlike permanent lentiviral approaches, repeatable dosing allows for adapting to tumor antigen escape and managing durability and safety over time. This flexibility is a core strategic advantage for complex diseases like solid tumors.